Drug Trial Radar · NCT01762839
A Study to Assess the Cardiac Safety of Oritavancin in Healthy Participants
Last checked: Nov 19, 2026Latest source record: Feb 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
150
Actual
Start
Dec 27, 2012
Primary completion
Jan 2013
Study completion Feb 11, 2013
Sponsor
- Lead sponsor
- Melinta Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 8, 2013
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of the study was to generate cardiac safety data using a supratherapeutic oritavancin dose of 1600 milligrams (mg).
Conditions
- Healthy
Interventions
Single-Dose IV Oritavancin DiphosphateDrug
Intravenous oritavancin was administered via 2 dedicated, peripheral venous lines, 1 in each arm. The infusion lasted approximately 3 hours.
PlaceboDrug
Intravenous placebo was administered via 2 dedicated, peripheral venous lines, 1 in each arm. The infusion lasted approximately 3 hours.
MoxifloxacinDrug
Participants randomized to the open-label moxifloxacin treatment arm only received a 400-mg moxifloxacin tablet and did not receive a placebo infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Placebo-adjusted change from Baseline in QTcFTime frame: predose, 3,3.5,4,5,6,7,9,11,15,24 hours post infusion start time
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Spaulding Clinical
West Bend, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.